Live from ClinicalTrials.gov + Open Targets, fetched 2026-11-11 19:27 UTC. Every row links to its source record.
Postmortem · what the sponsor and named sources said, kept apart from what merely happened at the same time
A Pilot Study Evaluating Safety of Sitagliptin Combined With Peg-IFN Alfa-2a + Ribavirin in Chronic Hepatitis C Patients
NCT01567540 · Institut National de la Santé Et de la Recherche Médicale, France · PHASE1 · terminated · last registry update 2026-10-07 · Decision brief
No research has been run for this trial yet, so only the registry's own reason and the timeline are shown.
What was said, and by whom
Stated is the sponsor's own words; Reported is a named third party. The category is our label from a fixed list; the quote is the evidence.
| Kind | Quote | Our category | Source |
|---|---|---|---|
| Stated | “New treatments available, which prevents additional recruitment.” | – | Registry record, Institut National de la Santé Et de la Recherche Médicale, France |
Also happening at the time. Not shown to be a cause.
Registry events on other trials of drugs against DPP4 within 12 months either side of this trial's last update, live from ClinicalTrials.gov. Nothing here was stated as a reason.
- 2026-10-16Also stopped (withdrawn): Sun Yat-sen University, Dorzagliatin + Linagliptin (NCT07786571)
- 2026-10-01Phase 3 first posted: Tanta University, Doxorubicin + Empaglifloz 5 mg orally once daily (NCT07852546)
- 2026-09-09Phase 3 first posted: Tanta University, Metformin + Vildagliptin (Galvus) (NCT07811011)
- 2026-08-18Also stopped (terminated): REDNVIA Co., Ltd., Evogliptin + Placebo (NCT05143177)
- 2026-08-03Results posted on the registry: Hoffmann-La Roche, 5-Fluorouracil (5-FU) + Leucovorin (NCT03281369)
- 2026-08-03Also stopped (terminated): Hoffmann-La Roche, 5-Fluorouracil (5-FU) + Leucovorin (NCT03281369)
- 2026-06-09Phase 3 first posted: Sun Yat-sen University, Group A (triple combination intensive therapy group) + Group B (standard therapy group) (NCT07635953)
- 2026-05-12Results posted on the registry: Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-05-12Also stopped (terminated): Hoffmann-La Roche, Atezolizumab + Cobimetinib (NCT03337698)
- 2026-02-10Results posted on the registry: GRADE Study Group, Sulfonylurea (glimepiride) + DPP-4 inhibitor (sitagliptin) (NCT01794143)
- 2026-01-28Results posted on the registry: Mayo Clinic, Sitagliptin + Dapagliflozin (NCT06263673)
- 2025-12-18Also stopped (withdrawn): Eurofarma Laboratorios S.A., N0892 + Januvia® + Glifage XR® + Placebo (NCT06560333)
What is not public
- Internal portfolio and board discussions
- Unpublished trial data and interim analyses
- Terms of any partner or licence decision